Prelude Capital Management, LLC Seagen Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $2.26 Million - $2.55 Million	11,814 Added 35.17%	45,404 $9.63 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $2.27 Million - $2.49 Million	12,072 Added 56.1%	33,590 $6.46 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $2.52 Million - $4.01 Million	19,759 Added 1123.31%	21,518 $4.36 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $825,932 - $979,339	-7,037 Reduced 80.0%	1,759 $226,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $318,019 - $423,438	-2,351 Reduced 21.09%	8,796 $1.2 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $1.21 Million - $2 Million	11,147 New	11,147 $1.97 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $289,071 - $344,754	-2,140 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $294,271 - $408,312	2,140 New	2,140 $297,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.